scholarly article | Q13442814 |
P356 | DOI | 10.1016/J.DADM.2018.05.003 |
P8608 | Fatcat ID | release_lnfq4w4eonhvnemblznph3bzl4 |
P932 | PMC publication ID | 6072672 |
P698 | PubMed publication ID | 30094328 |
P50 | author | Lu Hu | Q87713031 |
P2093 | author name string | Eric McDade | |
Jennifer H Lingler | |||
Oscar L Lopez | |||
Hyejin Kim | |||
J Scott Roberts | |||
Jonna L Morris | |||
Meghan Mattos | |||
P2860 | cites work | A rating scale for depression | Q24564540 |
Living With Ambiguity: A Metasynthesis of Qualitative Research on Mild Cognitive Impairment | Q26796506 | ||
Attitudes of Research Participants and the General Public Regarding Disclosure of Alzheimer Disease Research Results | Q27345258 | ||
The diagnosis of mild cognitive impairment due to Alzheimer's disease: recommendations from the National Institute on Aging-Alzheimer's Association workgroups on diagnostic guidelines for Alzheimer's disease | Q29614406 | ||
Communicating mild cognitive impairment diagnoses with and without amyloid imaging | Q33640373 | ||
Benefits, harms, and costs for breast cancer screening after US implementation of digital mammography. | Q33792616 | ||
Unwarranted variations in healthcare delivery: implications for academic medical centres | Q33812581 | ||
Amnestic MCI Patients' Perspectives toward Disclosure of Amyloid PET Results in a Research Context. | Q33840562 | ||
Ethics of genetic and biomarker test disclosures in neurodegenerative disease prevention trials | Q35400583 | ||
Is prostate cancer screening cost-effective? A microsimulation model of prostate-specific antigen-based screening for British Columbia, Canada | Q35541638 | ||
Development of a process to disclose amyloid imaging results to cognitively normal older adult research participants | Q35595661 | ||
Amyloid imaging, risk disclosure and Alzheimer's disease: ethical and practical issues | Q35838385 | ||
A Survey of Knowledge and Views Concerning Genetic and Amyloid PET Status Disclosure | Q36719734 | ||
Development of a Standardized Approach to Disclosing Amyloid Imaging Research Results in Mild Cognitive Impairment | Q36883137 | ||
Clinical use of amyloid-positron emission tomography neuroimaging: Practical and bioethical considerations | Q36929890 | ||
Disclosure of amyloid imaging results to research participants: has the time come? | Q37135140 | ||
Psychometric Properties of a Decisional Capacity Screening Tool for Individuals Contemplating Participation in Alzheimer's Disease Research | Q37283104 | ||
Disclosure of positron emission tomography amyloid imaging results: A preliminary study of safety and tolerability. | Q38691914 | ||
Dyadic Analysis of Illness Perceptions Among Persons with Mild Cognitive Impairment and Their Family Members | Q39000411 | ||
Patient and caregiver reactions to clinical amyloid imaging. | Q39160016 | ||
Confidentiality in preclinical Alzheimer disease studies: when research and medical records meet | Q42006679 | ||
A new brief instrument for assessing decisional capacity for clinical research | Q46107319 | ||
Patient and Caregiver Assessment of the Benefits From the Clinical Use of Amyloid PET Imaging | Q46431433 | ||
Comprehension of an Elevated Amyloid Positron Emission Tomography Biomarker Result by Cognitively Normal Older Adults | Q47742387 | ||
Prevalence and classification of mild cognitive impairment in the Cardiovascular Health Study Cognition Study: part 1. | Q52004978 | ||
NIA-AA Research Framework: Toward a biological definition of Alzheimer's disease. | Q52589491 | ||
Invisible risks, emotional choices--mammography and medical decision making | Q85795417 | ||
P407 | language of work or name | English | Q1860 |
P921 | main subject | positron emission tomography | Q208376 |
P304 | page(s) | 413-420 | |
P577 | publication date | 2018-05-30 | |
P1433 | published in | Alzheimer's & dementia (Amsterdam, Netherlands) | Q27726390 |
P1476 | title | Amyloid positron emission tomography candidates may focus more on benefits than risks of results disclosure | |
P478 | volume | 10 |
Search more.